<p>Prime Medicine, Inc.（紐約證券交易所代碼：PRME - 獲取免費報告）在週二的午盤交易中下跌了 6.7%。該股票最低交易價格為 4.16 美元，最後交易價格為 4.20 美元。在交易中，共交易了 1,029,369 股，較平均交易量 2,403,093 股下降了 57%。該股票之前的收盤價為 4.50 美元。</p>
<p>獲取 <strong>Prime Medicine</strong> 警報：</p>
<h2>分析師評級變動</h2>
<ul>
<li>2024 年值得關注的 2 只基因編輯股票</li>
</ul>
<p>幾家研究公司最近對 PRME 進行了評估。Chardan Capital 將 Prime Medicine 的目標價格從 16.00 美元下調至 12.00 美元，並在 5 月 19 日的報告中對該股票給予了 “買入” 評級。JMP Securities 將 Prime Medicine 的目標價格從 10.00 美元下調至 6.00 美元，並在 5 月 20 日的報告中對該股票給予了 “市場表現優於大盤” 的評級。花旗集團在 5 月 27 日的報告中重申了 “中性” 評級，並將 Prime Medicine 的目標價格設定為 1.50 美元（之前為 10.00 美元）。HC Wainwright 在 5 月 20 日的報告中將 Prime Medicine 的評級從 “買入” 下調至 “中性”。最後，Wedbush 在 7 月 16 日的報告中重申了 “表現優於大盤” 的評級，並對 Prime Medicine 的股票設定了 8.00 美元的價格目標。一位研究分析師對該股票給予了賣出評級，三位給予了持有評級，四位給予了買入評級，還有一位給予了強烈買入評級。根據 MarketBeat.com 的數據，Prime Medicine 目前的平均評級為 “適度買入”，共識目標價格為 9.25 美元。</p>
<p><strong>獲取我們關於 Prime Medicine 的最新報告</strong></p>
<h2>Prime Medicine 下跌 3.0%</h2>
<p>該股票的市值為 5.8708 億美元，市盈率為-2.14，貝塔值為 2.38。該公司的 50 日簡單移動平均線為 2.88 美元，200 日簡單移動平均線為 2.31 美元。</p>
<h2>Prime Medicine 內部活動</h2>
<p>在其他 Prime Medicine 的新聞中，主要股東 David R. Liu 在 6 月 23 日的交易中購買了 21,000 股該公司的股票。該股票的平均購買成本為每股 2.16 美元，總價值為 45,360.00 美元。完成購買後，該內部人士直接持有公司 20,219,945 股，價值約為 43,675,081.20 美元。這筆交易代表了他們持股比例的 0.10% 的增加。該購買在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。此外，主要股東 Arch Venture Partners Xii, Llc 在 8 月 1 日的交易中購買了 3,030,300 股 Prime Medicine 股票。該股票的平均購買價格為每股 3.30 美元，總價值為 9,999,990.00 美元。交易完成後，該內部人士持有公司 6,230,300 股，價值為 20,559,990 美元。這代表了他們持股比例的 94.70% 的增加。該購買的披露信息可以在這裏找到。內部人士在上個季度購買了價值 10,110,240 美元的 3,093,300 股公司股票。內部人士持有公司 22.93% 的股票。</p>
<h2>Prime Medicine 的機構交易</h2>
<p>幾家對沖基金和其他機構投資者最近買賣了 PRME 的股票。Westwood Holdings Group Inc.在第四季度將其在 Prime Medicine 的持股比例增加了 96.5%。Westwood Holdings Group Inc.目前持有 883,129 股該公司的股票，價值為 2,579,000 美元，此前在該期間又購買了 433,653 股。Walleye Capital LLC 在第四季度將其在 Prime Medicine 的持股比例提高了 272.5%。Walleye Capital LLC 目前持有 403,739 股該公司的股票，價值為 1,179,000 美元，此前在上個季度又購買了 295,365 股。AQR Capital Management LLC 在第一季度將其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前持有 243,795 股該公司的股票，價值為 485,000 美元，此前在上個季度又購買了 227,749 股。T. Rowe Price Investment Management Inc.在第四季度將其在 Prime Medicine 的持股比例提高了 4.5%。T. Rowe Price Investment Management Inc.目前持有 3,977,828 股該公司的股票，價值為 11,616,000 美元，此前在上個季度又購買了 170,541 股。最後，Susquehanna Fundamental Investments LLC 在第四季度購買了價值 423,000 美元的 Prime Medicine 新股份。目前 70.37% 的股票由機構投資者和對沖基金持有。</p>
<h2>Prime Medicine 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Prime Medicine, Inc.是一家生物技術公司，通過部署基因編輯技術提供遺傳療法，以應對各種疾病。該公司提供 Prime Editors，包含 Cas 蛋白和逆轉錄酶的融合體的 Prime Editor 蛋白；以及 pegRNA，旨在將 Prime Editor 定位到特定的基因組位置，並提供用於對目標 DNA 序列進行所需編輯的模板。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票超過 Prime Medicine</li>
<li>標普 500 股票向投資者傳達了什麼市場信息？</li>
<li>應用數字：為什麼看漲押注的激增預示着一個新時代</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>Palantir 股票在超預期財報後飆升</li>
<li>如何投資 FAANG 股票</li>
<li>亞馬遜進入修正區：是時候恐慌還是勇敢？</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
<p>在考慮 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議他們現在購買，以便在更廣泛的市場注意到之前……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRME

<p>Prime Medicine（紐約證券交易所代碼：PRME）股價下跌 6.7%，至 4.20 美元，交易量較平均水平下降 57%。分析師們已調整目標價格，Chardan Capital 將其目標價從 16 美元下調至 12 美元，而花旗集團則設定了 1.50 美元的新目標。內部交易出現顯著購買，增加了持股比例。機構投資者持有 70.37% 的股份。該公司專注於使用基因編輯技術進行基因療法，市值為 5.8708 億美元，市盈率為-2.14</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report) traded down 6.7% during mid-day trading on Tuesday . The stock traded as low as $4.16 and last traded at $4.20. 1,029,369 shares were traded during trading, a decline of 57% from the average session volume of 2,403,093 shares. The stock had previously closed at $4.50.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（紐約證券交易所代碼：PRME - 獲取免費報告）在週二的午盤交易中下跌了 6.7%。該股票最低交易價格為 4.16 美元，最後交易價格為 4.20 美元。在交易中，共交易了 1,029,369 股，較平均交易量 2,403,093 股下降了 57%。該股票之前的收盤價為 4.50 美元。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 警報：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年值得關注的 2 只基因編輯股票</li>
</ul>
</div><p>Several research firms recently weighed in on PRME. Chardan Capital reduced their target price on shares of Prime Medicine from $16.00 to $12.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, May 19th. JMP Securities reduced their target price on shares of Prime Medicine from $10.00 to $6.00 and set a &#34;market outperform&#34; rating on the stock in a report on Tuesday, May 20th. Citigroup restated a &#34;neutral&#34; rating and set a $1.50 target price (down previously from $10.00) on shares of Prime Medicine in a report on Tuesday, May 27th. HC Wainwright lowered shares of Prime Medicine from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Tuesday, May 20th. Finally, Wedbush reiterated an &#34;outperform&#34; rating and issued a $8.00 price objective on shares of Prime Medicine in a report on Wednesday, July 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Prime Medicine presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.25.</p>
<div class="lb-trans"><p>幾家研究公司最近對 PRME 進行了評估。Chardan Capital 將 Prime Medicine 的目標價格從 16.00 美元下調至 12.00 美元，並在 5 月 19 日的報告中對該股票給予了 “買入” 評級。JMP Securities 將 Prime Medicine 的目標價格從 10.00 美元下調至 6.00 美元，並在 5 月 20 日的報告中對該股票給予了 “市場表現優於大盤” 的評級。花旗集團在 5 月 27 日的報告中重申了 “中性” 評級，並將 Prime Medicine 的目標價格設定為 1.50 美元（之前為 10.00 美元）。HC Wainwright 在 5 月 20 日的報告中將 Prime Medicine 的評級從 “買入” 下調至 “中性”。最後，Wedbush 在 7 月 16 日的報告中重申了 “表現優於大盤” 的評級，並對 Prime Medicine 的股票設定了 8.00 美元的價格目標。一位研究分析師對該股票給予了賣出評級，三位給予了持有評級，四位給予了買入評級，還有一位給予了強烈買入評級。根據 MarketBeat.com 的數據，Prime Medicine 目前的平均評級為 “適度買入”，共識目標價格為 9.25 美元。</p>
</div><p><strong>Get Our Latest Report on Prime Medicine</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Prime Medicine 的最新報告</strong></p>
</div><h2>Prime Medicine Trading Down 3.0%</h2>
<div class="lb-trans"><h2>Prime Medicine 下跌 3.0%</h2>
</div><p>The stock has a market cap of $587.08 million, a P/E ratio of -2.14 and a beta of 2.38. The firm's 50-day simple moving average is $2.88 and its 200 day simple moving average is $2.31.</p>
<div class="lb-trans"><p>該股票的市值為 5.8708 億美元，市盈率為-2.14，貝塔值為 2.38。該公司的 50 日簡單移動平均線為 2.88 美元，200 日簡單移動平均線為 2.31 美元。</p>
</div><h2>Insider Activity at Prime Medicine</h2>
<div class="lb-trans"><h2>Prime Medicine 內部活動</h2>
</div><p>In other Prime Medicine news, major shareholder David R. Liu bought 21,000 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The stock was acquired at an average cost of $2.16 per share, with a total value of $45,360.00. Following the completion of the purchase, the insider directly owned 20,219,945 shares in the company, valued at approximately $43,675,081.20. This trade represents a 0.10% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Arch Venture Partners Xii, Llc purchased 3,030,300 shares of Prime Medicine stock in a transaction that occurred on Friday, August 1st. The stock was purchased at an average price of $3.30 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 6,230,300 shares in the company, valued at $20,559,990. This represents a 94.70% increase in their position. The disclosure for this purchase can be found here. Insiders bought 3,093,300 shares of company stock valued at $10,110,240 over the last quarter. Insiders own 22.93% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Prime Medicine 的新聞中，主要股東 David R. Liu 在 6 月 23 日的交易中購買了 21,000 股該公司的股票。該股票的平均購買成本為每股 2.16 美元，總價值為 45,360.00 美元。完成購買後，該內部人士直接持有公司 20,219,945 股，價值約為 43,675,081.20 美元。這筆交易代表了他們持股比例的 0.10% 的增加。該購買在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。此外，主要股東 Arch Venture Partners Xii, Llc 在 8 月 1 日的交易中購買了 3,030,300 股 Prime Medicine 股票。該股票的平均購買價格為每股 3.30 美元，總價值為 9,999,990.00 美元。交易完成後，該內部人士持有公司 6,230,300 股，價值為 20,559,990 美元。這代表了他們持股比例的 94.70% 的增加。該購買的披露信息可以在這裏找到。內部人士在上個季度購買了價值 10,110,240 美元的 3,093,300 股公司股票。內部人士持有公司 22.93% 的股票。</p>
</div><h2>Institutional Trading of Prime Medicine</h2>
<div class="lb-trans"><h2>Prime Medicine 的機構交易</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of PRME. Westwood Holdings Group Inc. grew its position in shares of Prime Medicine by 96.5% during the 4th quarter. Westwood Holdings Group Inc. now owns 883,129 shares of the company's stock worth $2,579,000 after buying an additional 433,653 shares during the period. Walleye Capital LLC lifted its stake in Prime Medicine by 272.5% in the fourth quarter. Walleye Capital LLC now owns 403,739 shares of the company's stock valued at $1,179,000 after buying an additional 295,365 shares in the last quarter. AQR Capital Management LLC lifted its stake in Prime Medicine by 1,419.4% in the first quarter. AQR Capital Management LLC now owns 243,795 shares of the company's stock valued at $485,000 after buying an additional 227,749 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Prime Medicine by 4.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,977,828 shares of the company's stock valued at $11,616,000 after buying an additional 170,541 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Prime Medicine in the fourth quarter worth $423,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買賣了 PRME 的股票。Westwood Holdings Group Inc.在第四季度將其在 Prime Medicine 的持股比例增加了 96.5%。Westwood Holdings Group Inc.目前持有 883,129 股該公司的股票，價值為 2,579,000 美元，此前在該期間又購買了 433,653 股。Walleye Capital LLC 在第四季度將其在 Prime Medicine 的持股比例提高了 272.5%。Walleye Capital LLC 目前持有 403,739 股該公司的股票，價值為 1,179,000 美元，此前在上個季度又購買了 295,365 股。AQR Capital Management LLC 在第一季度將其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前持有 243,795 股該公司的股票，價值為 485,000 美元，此前在上個季度又購買了 227,749 股。T. Rowe Price Investment Management Inc.在第四季度將其在 Prime Medicine 的持股比例提高了 4.5%。T. Rowe Price Investment Management Inc.目前持有 3,977,828 股該公司的股票，價值為 11,616,000 美元，此前在上個季度又購買了 170,541 股。最後，Susquehanna Fundamental Investments LLC 在第四季度購買了價值 423,000 美元的 Prime Medicine 新股份。目前 70.37% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.是一家生物技術公司，通過部署基因編輯技術提供遺傳療法，以應對各種疾病。該公司提供 Prime Editors，包含 Cas 蛋白和逆轉錄酶的融合體的 Prime Editor 蛋白；以及 pegRNA，旨在將 Prime Editor 定位到特定的基因組位置，並提供用於對目標 DNA 序列進行所需編輯的模板。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>Applied Digital: Why a Surge in Bullish Bets Signals a New Era</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Palantir Stock Soars After Blowout Earnings Report</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Amazon Enters Correction Zone: Time to Panic or Be Brave?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Prime Medicine</li>
<li>標普 500 股票向投資者傳達了什麼市場信息？</li>
<li>應用數字：為什麼看漲押注的激增預示着一個新時代</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>Palantir 股票在超預期財報後飆升</li>
<li>如何投資 FAANG 股票</li>
<li>亞馬遜進入修正區：是時候恐慌還是勇敢？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議他們現在購買，以便在更廣泛的市場注意到之前……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Prime Medicine（NYSE 代碼：PRME）股價下跌 6.7% - 以下是事件的經過